Navigation Links
Trinity Health Selects Seven Elsevier Clinical Decision Support Solutions for its Multiple Facilities In Seven States
Date:11/10/2009

ies to publish more than 2,000 journals, including The Lancet (http://www.thelancet.com) and Cell (http://www.cell.com), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect (http://www.sciencedirect.com), Scopus (http://www.scopus.com), Reaxys (http://www.reaxys.com), MD Consult (http://www.mdconsult.com) and Nursing Consult (http://www.nursingconsult.com), which enhance the productivity of science and health professionals, and the SciVal suite (http://www.scival.com) and MEDai's Pinpoint Review (http://www.medai.com), which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier (http://www.elsevier.com) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC (http://www.reedelsevier.com), a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

About Trinity Health

Trinity Health is the fourth-largest Catholic health care system in the country. Based in Novi, Mich., Trinity Health operates 44 acute-care hospitals, 379 outpatient facilities, 33 long-term care facilities, and numerous home health offices and hospice programs in eight states. Employing 45,800 full-time staff, Trinity Health reported $7.0 billion in unrestricted revenue
'/>"/>

SOURCE Elsevier
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Central and Eastern European Healthcare Markets Hold Strong Potential for Growth Despite the Economic Slowdown, Says Frost & Sullivan
2. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
3. Womens Sexual Health Company Changes Name in Preparation for Market Entry
4. LifeNet Health Announces First Bio-Implant with New Preservation Technology
5. Clarient to Present at Upcoming Healthcare Investor Conferences in New York City
6. Recession Continues to Depress Sales at Allied Healthcare Products
7. McNeil Consumer Healthcare Announces Voluntary Recall of Certain Lots of TYLENOL(R) Arthritis Pain 100 Count with EZ-OPEN CAP
8. Watson to Present at Credit Suisse Healthcare Conference
9. Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results
10. Statement of Americas Specialty Medicines Companies On House Health Care Bill (H.R. 3962)
11. OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... ATLANTA , March 30, 2015  Edelberg ... the first of its kind, real-time medical coding ... the patient, physician, scribe and medical coder at ... lengthy collaboration initiative with ScribeAmerica, EA has successfully ... method for real-time interaction between scribe and medical ...
(Date:3/30/2015)... March 30, 2015 DURECT Corporation (Nasdaq: ... initiated a multi-dose Phase 1 clinical trial of ... in DURECT,s Epigenomic Regulator Program.  DUR-928 is an ... have broad applicability in metabolic diseases such as ... (NASH).  It may also play an important role ...
(Date:3/30/2015)... Israel , March 30, 2015   GlassesUSA , ... the closing of $12.5 million in new financing led by ... Group. The funding will further GlassesUSA,s aggressive business growth and ... global market of online eyewear, both B2C and B2B. ... Rothman , COO Eldad Rothman , and CTO ...
Breaking Medicine Technology:Edelberg & Associates and ScribeAmerica Partner to Launch Healthcare Industry's First Ever Real-time Medical Coding Solution 2Edelberg & Associates and ScribeAmerica Partner to Launch Healthcare Industry's First Ever Real-time Medical Coding Solution 3DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 2DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 3DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 4GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 2GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 3
... For women who would like to have,children but who ... time in,their lives, the door to a new option has ... known as,vitrification, a quick freezing method, is a safe means ... exhaustive study yet on the,subject, the new study revealed that ...
... BioPharma, Inc.,(OTC: CBIA), is pleased to announce that ... for a Phase II study in 30 cancer,patients ... tract from radiation-induced mucositis. This new trial is,an ... as a novel,preventative, anti-mucositis agent., Oral and ...
Cached Medicine Technology:New Research Just Released: Women Can Now Safely Postpone Motherhood Until Time Is Right 2CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck 2
(Date:3/30/2015)... 2015 Healthy, radiant skin can be ... staff of pharmacists is specially trained and skilled in ... eczema and other conditions. , Most people are unaware ... and/or PCP to tackle most skin conditions and offer ... employed specialty-trained pharmacists who have experience in consulting with ...
(Date:3/30/2015)... 2015 In a recent report published ... Chris Christie is championing effective drug and alcohol treatment ... scrambling to recover funds to stabilize the addiction treatment ... victims of drug and alcohol addiction. Harbor Village Detox ... by substance use disorders in New Jersey, in hopes ...
(Date:3/30/2015)... Jose, California (PRWEB) March 30, 2015 ... population and government efforts to develop and establish chronic ... management therapies. Growth in the market is poised to ... as a result of the increase in chronic health ... diseases, and rheumatoid arthritis, among others. While conventional treatment ...
(Date:3/30/2015)... New York (PRWEB) March 30, 2015 Recently, ... Top 10 Exotic Water Awards, with the top three winners ... are listed on the company’s website, along with other informative ... exotic water, glacial water, spring water, mineral water and sparkling ... water is one of the top exotic water brands ...
(Date:3/30/2015)... Valerie Harper, the actress best known as ... Mary Tyler Moore Show,” will be the keynote speaker ... magazine announced today. Harper, who is living with terminal ... 40th Annual Congress on April 23 in Orlando, Fla. ... play in the lives of people with cancer. Nominated ...
Breaking Medicine News(10 mins):Health News:MedX Pharmacy Offers Skin Care Tips 2Health News:Harbor Village Detox Extends Addiction Treatment to NJ & Suggests 7 Ways to Find the Best Recovery Center 2Health News:Harbor Village Detox Extends Addiction Treatment to NJ & Suggests 7 Ways to Find the Best Recovery Center 3Health News:Technological Developments, Better Patient Awareness & Affordability Drive the Pain Management Devices Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Technological Developments, Better Patient Awareness & Affordability Drive the Pain Management Devices Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Best Exotic Water Brands Acclaimed by 10 Best Water 2Health News:Spunky Sitcom Star and Lung Cancer Survivor Valerie Harper to Keynote Extraordinary Healer™ Award Ceremony Honoring Oncoloy Nurses 2Health News:Spunky Sitcom Star and Lung Cancer Survivor Valerie Harper to Keynote Extraordinary Healer™ Award Ceremony Honoring Oncoloy Nurses 3
... Dissolving Film StripBioAlliance to Resubmit Loramyc(R) NDA WOODCLIFF LAKE, ... division of a wholly owned subsidiary of Par Pharmaceutical ... an update on two of its pipeline products. ... 2009, Strativa submitted a New Drug Application (NDA) for ...
... a manufacturer of advanced cell imaging systems, announced ... The patent, entitled Blood and Cell Analysis Using ... of multispectral cell imaging in flow or on ... to 32 issued U.S. patents plus multiple foreign ...
... Boston Scientific Corporation (NYSE: BSX ) today announced financial results ... for net sales and earnings per share (EPS) for the second quarter ... growth rates are constant currency): , , ... EPS of $0.19, both in line with guidance (GAAP loss per share ...
... protection against application layer threats and satisfies compliance ... leading Security as a Service Provider, today launched ... service that detects and blocks threats targeting Web ... rely on Web applications and Web 2.0 technologies ...
... announces the recent addition of Beth Joy-Dougherty as Director, ... responsible for further development and growth of CXHC, including ... to CXHC with more than 16 years of pharmaceutical ... Director of Key Account Development for Poretta & Orr, ...
... Corporation (Nasdaq: PODD ), the leader in ... System, announced plans to release its financial results for ... after the close of the financial markets.Insulet will also ... on Thursday, May 7, 2009 to discuss its first ...
Cached Medicine News:Health News:Strativa Pharmaceuticals Provides Product Pipeline Update 2Health News:Strativa Pharmaceuticals Provides Product Pipeline Update 3Health News:Strativa Pharmaceuticals Provides Product Pipeline Update 4Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 2Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 3Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 4Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 5Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 6Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 7Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 8Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 9Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 10Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 11Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 12Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 13Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 14Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 15Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 16Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 17Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 18Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 19Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 20Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 21Health News:SecureWorks, Inc. Launches Managed Web Application Firewall Service 2Health News:SecureWorks, Inc. Launches Managed Web Application Firewall Service 3Health News:Beth Joy-Dougherty Joins CONNEXION Healthcare as Director, New Business Development 2Health News:Insulet Corporation to Report First Quarter 2009 Financial Results on Thursday, May 7, 2009 2
... The CellTracks® Analyzer II ... microscope used to enumerate ... are immunomagnetically selected and ... of the CellTracks® Analyzer ...
... sps. is now recognized as an ... HIV infection. Routine parasitological techniques fail ... Fast staining techniques prove effective in ... have many typical organisms on each ...
... Slides have a positive and negative inoculated ... With these slides, perform QC and sample ... their education and training programs by testing ... all on one slide! KWIK-QC slides contain ...
Each slide contains an A.F.B. positive staining control of Mycobacterium scrofulaceum ATCC ® 19981 in simulated sputum and an A.F.B. negative staining control of Escherichia coli ATCC ® 25922...
Medicine Products: